InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) Goes Above $2 Again

After a few red sessions in the beginning of December, the stock of InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) dove below the $2 per share mark and landed as low as $1.54 on December 6.

Since then, NVIV started to regain its value and the regular news coming from the company seem to be enough to keep up the hype. Volumes of traded stock were below the average in the 100-200 thousand traded shares range, but things changed lately.

Recent positive news in which NVIV announced that they have received a Conditional Approval from the FDA and hopes of commencement of the treatment of patiets with their polymer scaffold for spinal cord injuries in the first half of March were enough to attract more investor interest.

Recently, the volumes have skyrocketed and NVIV traded in as much as 1 million shares in the session after Christmas and generated a trade value of a whopping $2.2 million.

The last day before the weekend went slower, but NVIV added another 11% to its value. The total amount of shares that switched hands while the ticker was going for a close at $2.41 came at 561 thousand and generated a good $1.3 million in dollar volume.

NVIV, however, remains a volatile stock that may sway in both directions depending on the optimism coming from the news, because the company is yet to produce any revenues.

In any case, be sure to do a lot of due diligence and weigh out the risks, because the price is already quite high for such a stock.

Timios National Corp (OTCMKTS:HOMS) also made a pretty good jump before the weekend and added 54% to its value while being heavily promoted. Xumanii International Holdings Corp (OTCMKTS:XUII) on the other hand, registered another session in the red as the ticker lost a quarter of its value.